Well that's very good news. They are on track to deliver the trial results in Q1 as promised. And good to see them at least mention the other projects, though it confirms my suspicions: FXS will be slow, and we can forget about TBI/concussion at this stage.
I don't have any obvious problems with the Lang Walker placement, the interesting thing is the date. What it tells me is that the future of the company should be determined, more or less, by the middle of next year.
Ann: Neuren completes enrolment in Rett syndrome Phase 2 trial, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.98 |
Change
0.125(0.97%) |
Mkt cap ! $1.617B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.85 | $7.044M | 538.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2732 | $13.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.20 | 351 | 3 |
View Market Depth
| Last trade - 15.59pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |